Sentiment for Advanta Home Equity Loan Trust 1993-3 (NASDAQ:IART)
Advanta Home Equity Loan Trust 1993-3 (NASDAQ:IART) institutional sentiment increased to 1.27 in Q1 2019. Its up 0.06, from 1.21 in 2018Q4. The ratio is positive, as 112 institutional investors increased or opened new stock positions, while 88 sold and decreased their equity positions in Advanta Home Equity Loan Trust 1993-3. The institutional investors in our partner’s database now own: 69.24 million shares, down from 70.91 million shares in 2018Q4. Also, the number of institutional investors holding Advanta Home Equity Loan Trust 1993-3 in their top 10 stock positions increased from 1 to 2 for an increase of 1. Sold All: 18 Reduced: 70 Increased: 73 New Position: 39.
Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $4.65 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 56.76 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
The stock decreased 0.77% or $0.42 during the last trading session, reaching $54.43. About 328,249 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has declined 20.92% since July 20, 2018 and is downtrending. It has underperformed by 25.35% the S&P500.
Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on July, 24. They expect $0.65 earnings per share, up 8.33 % or $0.05 from last year’s $0.6 per share. IART’s profit will be $55.57 million for 20.93 P/E if the $0.65 EPS becomes a reality. After $0.65 actual earnings per share reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.
Champlain Investment Partners Llc holds 2.66% of its portfolio in Integra LifeSciences Holdings Corporation for 5.47 million shares. Falcon Point Capital Llc owns 80,729 shares or 2.45% of their US portfolio. Moreover, Tributary Capital Management Llc has 2.06% invested in the company for 508,838 shares. The New York-based Broadfin Capital Llc has invested 1.63% in the stock. Mesirow Financial Investment Management, a Alabama-based fund reported 182,585 shares.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage
Ratings analysis reveals 43% of Integra Lifesciences’s analysts are positive. Out of 7 Wall Street analysts rating Integra Lifesciences, 3 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $50 while the high is $65. The stock’s average target of $60.14 is 10.49% above today’s ($54.43) share price. IART was included in 11 notes of analysts from February 21, 2019. The firm has “Buy” rating given on Tuesday, February 26 by JMP Securities. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, March 11. Morgan Stanley maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Friday, February 22 with “Hold” rating. The stock has “Buy” rating by Piper Jaffray on Thursday, February 21. BTIG Research maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating on Thursday, February 21. BTIG Research has “Buy” rating and $65 target. Citigroup maintained the stock with “Hold” rating in Friday, February 22 report. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Hold” rating by Cantor Fitzgerald on Thursday, February 21. The company was maintained on Friday, February 22 by RBC Capital Markets. Piper Jaffray maintained the shares of IART in report on Monday, March 11 with “Buy” rating.
More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Nasdaq.com which released: “Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy? – Nasdaq” on July 17, 2019, also Benzinga.com with their article: “The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs – Benzinga” published on April 21, 2019, Seekingalpha.com published: “Integra LifeSciences Q1 top line up 1%; GAAP EPS guidance raised – Seeking Alpha” on April 24, 2019. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Gurufocus.com and their article: “Jul 19, 2019 – Commonwealth Equity Services, Llc. Buys First Trust Capital Strength ETF, iShares Core Dividend Growth, Invesco S&P 500 High Dividend Low Volatility, Sells SPDR Select Sector Fund – Health Care, First Trust Health Care AlphaDEX, iShares S&P Mid-Cap 400 Va – GuruFocus.com” published on July 19, 2019 as well as Seekingalpha.com‘s news article titled: “Integra LifeSciences Holdings (IART) Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: July 25, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.